Analysis of Non-genetic Factors Influencing the Overall Survival of Multiple Myeloma Patients.
10.19746/j.cnki.issn.1009-2137.2020.06.025
- Author:
Lin GUI
1
;
Bao-An CHEN
2
;
Chong GAO
3
;
Fei WANG
3
;
Jin-Ning SHI
4
Author Information
1. Department of Hematology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China，Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, Jiangsu Province, China.
2. Department of Hematology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China,E-mail: cba8888@hotmail.com.
3. Department of Hematology, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu Province, China.
4. Department of Hematology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 211100, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Female;
Humans;
Male;
Multiple Myeloma/genetics*;
Patients;
Prognosis;
Proportional Hazards Models;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(6):1946-1951
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the non-genetic factors of overall survival in patients with multiple myeloma (MM).
METHODS:Kaplan-Meier survival curve, Log-rank test and Cox regression model were used to carry out univariate and multivariate retrospective analysis on clinical and laboratory parameters of 51 patients who were newly diagnosed with MM and had complete follow-up data in the Department of Hematology, the Affiliated Jiangning Hospital of Nanjing Medical University from November 2011 to October 2019.
RESULTS:Fifty-one patients included 29 males and 22 females. Followed up to December 2019, 21 cases died and 30 cases survived. The univariate analysis showed that the overall survival time of the patients was influenced by age, disease stage, standard treatment, new drugs, maintenance treatment, hypercalcemia, globulin, albumin, and hemoglobin. The overall survival time of patients with age <65 years old, ISS stage I and II, standardized treatment, new drugs, normal or below normal blood calcium, normal or below normal globulin, albumin ≥35 g/L or hemoglobin ≥100 g/L was prolonged significantly (P<0.05). The multivariate analysis showed that maintenance treatment, hypercalcemia (≥2.6 mmol/L), and hemoglobin (<100 g/L) were independent risk factors influencing the prognosis of MM patients.
CONCLUSION:Patients with blood calcium ≥2.6 mmol/L, hemoglobin <100 g/L, and who do not undergo regular maintenance therapy show a poor prognosis.
